Expansion opportunities Capitalizing on their FDA Breakthrough Device designation and recent educational collaborations, PreludeDx could pursue partnerships with payer networks and hospital systems to scale adoption of DCISionRT and AidaBreast tests, emphasizing real-world outcomes and cost savings in DCIS management.

Key partnerships Leverage ongoing collaborations with Learn Look Locate and education-focused platforms to co-develop payer-proven education and patient decision aids, creating joint offerings that drive referral volume from breast cancer centers and community hospitals.

Clinical leadership With senior appoints in medical affairs and operations, there is an opening to engage KOLs and tumor boards for study participation, guideline alignment, and early-access programs that can widen test adoption among clinicians treating DCIS and early-stage breast cancer.

Technology leverage Highlight the scalable cloud and analytics stack to support partner labs and health systems in integrating DCISionRT workflows with existing EHRs and decision-support tools, enabling smoother implementation and data-driven care pathways.

Financial scale Given mid-market revenue and moderate funding, target mid-sized breast cancer centers and regional health systems seeking high-value diagnostics, offering bundled pricing, outcomes-based contracts, and education resources to accelerate sales cycles.